Strategy question
Abridge must decide whether to build, license, or partner for new evidence sources such as guidelines, journals, or point-of-care references. Walk through the decision framework you would use for one new source, including quality, coverage, workflow fit, differentiation, economics, and the threshold that must be met before you would allow that source into a high-stakes clinical product.
- Abridge
- Strategy
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Tests building a decision framework for sourcing new clinical evidence content, weighing quality, coverage, workflow fit, and economics against the threshold required for a high-stakes clinical product.
How to approach it
- Set quality as a hard gate first: the source must meet a defined standard of clinical rigor and currency, like peer-reviewed or actively maintained guideline status, before anything else is weighed.
- Assess coverage: does the source fill a genuine gap, like a specialty not well covered today, versus overlapping with existing sources.
- Assess workflow fit: can the content be integrated into the existing chat and documentation workflow usefully in the moment, not just as a static reference link.
- Assess differentiation and economics together: does licensing this source create real advantage worth its ongoing cost versus a cheaper or already-covered alternative.
- Choose build only if quality, freshness, or fit can't be met by any existing external source; license or partner when a trusted source already meets the quality bar.
- Set the threshold explicitly: a source doesn't enter the product unless it clears the quality gate and shows clear incremental value, regardless of how attractive the economics look.
What a strong answer includes
- Treats clinical quality as a strict hard gate, refusing to trade it off against cost or speed for a high-stakes product.
- Separates coverage gap analysis from economics, avoiding a source that duplicates existing coverage just because it's cheap to add.
- Frames build versus license as driven by whether existing sources meet quality and fit needs, not a default preference for building in-house.
Common mistakes
- Letting attractive economics or speed override the clinical quality gate for a high-stakes product.
- Adding a source that overlaps significantly with existing coverage without real incremental value.
- Defaulting to build in-house without checking whether a trusted external source already meets the need.
Likely follow-up questions
- How would you handle a source that's excellent on quality but has restrictive licensing terms?
- What would make you remove a previously approved source later?
More strategy questions
- Abridge can solve a clinical documentation workload with four options: a frontier API, an open-source model, a prompted/routed workflow, or an in-house trained model. Build a decision framework for choosing among them. Which criteria would be hard gates versus tradeoff variables, and how would you weigh durable strategic advantage against near-term speed, quality, latency, cost, safety, and controllability?Abridge · Strategy · Hard
- For a core workflow in Epic, how would you decide whether to build the experience embedded inside the EHR, in a standalone Abridge surface, or as a hybrid? Compare the options on clinician adoption, workflow speed, integration constraints, release velocity, data access, and defensibility, and explain how your choice would shape the roadmap.Abridge · Strategy · Hard
- You need to introduce eval gates from prototype to GA to steady-state monitoring across teams you do not manage directly. How would you set hard vs. advisory gates, assign ownership for non-negotiable floors like critical-error rates, and drive adoption across pods without slowing shipping velocity?Abridge · Strategy · Hard
- A CMIO is pushing for a bespoke feature that would materially help their deployment, but you believe it will not generalize to Abridge’s core product. What decision framework would you use to choose between building it in the forward-deployed engagement, declining it, or routing it to the core roadmap, and how would you communicate that decision without damaging the relationship?Abridge · Strategy · Hard
- You are two weeks into a six-week forward-deployed engagement when three things happen at once: the partner asks for additional scope, engineering finds an integration blocker, and executives want a firm go-live date. How would you re-scope the work, protect pod focus and pace, make the right trade-offs, and keep hospital leadership aligned on an outcome that is still worth shipping?Abridge · Strategy · Hard
- Google Keep is a free product to save, share notes etc. How would you make it a subscription product & monetize it?Google · Strategy · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 4: Discovery and strategy for AI products
- Chapter 9: Prove it paid off: outcomes, economics, and pricing
- Chapter 14: Get the job: the AI PM interview loop